This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


5kr0

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (12:41, 6 March 2024) (edit) (undo)
 
(4 intermediate revisions not shown.)
Line 1: Line 1:
==Protease E35D-APV==
==Protease E35D-APV==
-
<StructureSection load='5kr0' size='340' side='right' caption='[[5kr0]], [[Resolution|resolution]] 1.80&Aring;' scene=''>
+
<StructureSection load='5kr0' size='340' side='right'caption='[[5kr0]], [[Resolution|resolution]] 1.80&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>[[5kr0]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5KR0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5KR0 FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[5kr0]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5KR0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5KR0 FirstGlance]. <br>
-
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=478:{3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC+ACID+TETRAHYDRO-FURAN-3-YL+ESTER'>478</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.8&#8491;</td></tr>
-
<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=UNK:UNKNOWN'>UNK</scene></td></tr>
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=478:{3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC+ACID+TETRAHYDRO-FURAN-3-YL+ESTER'>478</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr>
-
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5kqx|5kqx]], [[5kqy|5kqy]], [[5kqz|5kqz]], [[5kr1|5kr1]], [[5kr2|5kr2]]</td></tr>
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5kr0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5kr0 OCA], [https://pdbe.org/5kr0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5kr0 RCSB], [https://www.ebi.ac.uk/pdbsum/5kr0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5kr0 ProSAT]</span></td></tr>
-
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5kr0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5kr0 OCA], [http://pdbe.org/5kr0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5kr0 RCSB], [http://www.ebi.ac.uk/pdbsum/5kr0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5kr0 ProSAT]</span></td></tr>
+
</table>
</table>
-
<div style="background-color:#fffaf0;">
+
== Function ==
-
== Publication Abstract from PubMed ==
+
[https://www.uniprot.org/uniprot/C8BD48_9HIV1 C8BD48_9HIV1]
-
Multidrug resistance to current FDA approved HIV-1 protease (PR) inhibitors drives the need to understand the fundamental mechanisms of how drug-pressure selected mutations, which are oftentimes natural polymorphisms, elicit their effect on enzyme function and resistance. Here, the impact of hinge-region natural polymorphism at residue 35 - glutamate to aspartate (E35D) - alone and in conjunction with residue 57 arginine to lysine (R57K) are characterized with the goal of understanding how altered salt-bridge interactions between the hinge and flap regions are associated with changes in structure, motional dynamics, conformational sampling, kinetic parameters, and inhibitor affinity. The combined results reveal that the single E35D substitution leads to diminished salt-bridge interactions between residue 35 and 57 and gives rise to the stabilization of open-like conformational states with overall increased backbone dynamics. In HIV-1 PR constructs where sites 35 and 57 are both mutated (e.g. E35D, R57K), X-ray structures reveal an altered network of interactions that replace the salt-bridge thus stabilizing the structural integrity between the flap and hinge regions. In spite of the altered conformational sampling and dynamics when the salt bridge is disrupted, enzyme kinetic parameters and inhibition constants are similar to those obtained for subtype B PR. Results demonstrate that these hinge region natural polymorphisms, which may arise as drug pressure secondary mutations, alter protein dynamics and conformational landscape, which are important thermodynamic parameters to consider for development of inhibitors that target for non-subtype B PR.
+
-
Effects of Hinge Region Natural Polymorphisms on Human Immunodeficiency Virus-1 Protease Structure, Dynamics and Drug-Pressure Evolution.,Liu Z, Huang X, Hu L, Pham L, Poole KM, Tang Y, Mahon BP, Tang W, Li K, Goldfarb NE, Dunn BM, McKenna R, Fanucci GE J Biol Chem. 2016 Aug 30. pii: jbc.M116.747568. PMID:27576689<ref>PMID:27576689</ref>
+
==See Also==
-
 
+
*[[Immunodeficiency virus protease 3D structures|Immunodeficiency virus protease 3D structures]]
-
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
+
-
</div>
+
-
<div class="pdbe-citations 5kr0" style="background-color:#fffaf0;"></div>
+
-
== References ==
+
-
<references/>
+
__TOC__
__TOC__
</StructureSection>
</StructureSection>
-
[[Category: Fanucci, G E]]
+
[[Category: Human immunodeficiency virus 1]]
-
[[Category: Liu, Z]]
+
[[Category: Large Structures]]
-
[[Category: Mahon, B P]]
+
[[Category: Fanucci GE]]
-
[[Category: McKenna, R]]
+
[[Category: Liu Z]]
-
[[Category: Poole, K M]]
+
[[Category: Mahon BP]]
-
[[Category: E35d]]
+
[[Category: McKenna R]]
-
[[Category: Hiv-1 protease]]
+
[[Category: Poole KM]]
-
[[Category: Hydrolase-hydrolase inhibitor complex]]
+
-
[[Category: Natural polymorphism]]
+
-
[[Category: Salt-bridge interaction]]
+

Current revision

Protease E35D-APV

PDB ID 5kr0

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/5kr0"
Personal tools